BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11850 related articles for article (PubMed ID: 12528807)

  • 1. Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials.
    Neuber K
    Recent Results Cancer Res; 2003; 161():159-79. PubMed ID: 12528807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo.
    Neuber K; tom Dieck A; Blödorn-Schlicht N; Itschert G; Karnbach C
    Melanoma Res; 1999 Apr; 9(2):125-32. PubMed ID: 10380934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial.
    Neuber K; Reinhold U; Deutschmann A; Pföhler C; Mohr P; Pichlmeier U; Baumgart J; Hauschild A
    Melanoma Res; 2003 Feb; 13(1):81-5. PubMed ID: 12569289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitivity testing in malignant melanoma.
    Ugurel S; Tilgen W; Reinhold U
    Recent Results Cancer Res; 2003; 161():81-92. PubMed ID: 12528801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
    Spieth K; Kaufmann R; Gille J
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):377-82. PubMed ID: 12879280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
    Ugurel S; Schadendorf D; Pföhler C; Neuber K; Thoelke A; Ulrich J; Hauschild A; Spieth K; Kaatz M; Rittgen W; Delorme S; Tilgen W; Reinhold U;
    Clin Cancer Res; 2006 Sep; 12(18):5454-63. PubMed ID: 17000680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
    Atzpodien J; Terfloth K; Fluck M; Reitz M
    Br J Cancer; 2007 Nov; 97(10):1329-32. PubMed ID: 17971774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treosulfan in the treatment of metastatic renal cell carcinoma.
    Rigos D; Wechsel HW; Bichler KH
    Anticancer Res; 1999; 19(2C):1549-52. PubMed ID: 10365143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
    Pföhler C; Cree IA; Ugurel S; Kuwert C; Haass N; Neuber K; Hengge U; Corrie PG; Zutt M; Tilgen W; Reinhold U
    Anticancer Drugs; 2003 Jun; 14(5):337-40. PubMed ID: 12782938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.
    Meden H; Wittkop Y; Kuhn W
    Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma.
    Cree IA; Neale MH; Myatt NE; de Takats PG; Hall P; Grant J; Kurbacher CM; Reinhold U; Neuber K; MacKie RM; Chana J; Weaver PC; Khoury GG; Sartori C; Andreotti PE
    Anticancer Drugs; 1999 Jun; 10(5):437-44. PubMed ID: 10477162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
    Neale MH; Myatt N; Cree IA; Kurbacher CM; Foss AJ; Hungerford JL; Plowman PN
    Br J Cancer; 1999 Mar; 79(9-10):1487-93. PubMed ID: 10188895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
    Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma.
    Schmittel A; Schuster R; Bechrakis NE; Siehl JM; Foerster MH; Thiel E; Keilholz U
    Melanoma Res; 2005 Oct; 15(5):447-51. PubMed ID: 16179873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study.
    Chekerov R; Kaltenecker G; Reichert D; Göhler T; Klare P; Oskay-Özcelik G; Sauer U; Wischnik A; Vehling-Kaiser U; Becker M; Hutzschenreuter U; Ammon A; Heidrich-Lorsbach E; Sehouli J
    Anticancer Res; 2015 Dec; 35(12):6869-75. PubMed ID: 26637909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.
    Corrie PG; Shaw J; Spanswick VJ; Sehmbi R; Jonson A; Mayer A; Bulusu R; Hartley JA; Cree IA
    Br J Cancer; 2005 Jun; 92(11):1997-2003. PubMed ID: 15886706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treosulfan chemotherapy for recurrent malignant glioma.
    Schmidt F; Wick W; Herrlinger U; Dichgans J; Weller M
    J Neurooncol; 2000 Sep; 49(3):231-4. PubMed ID: 11212902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
    Atzpodien J; Terfloth K; Fluck M; Reitz M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):685-8. PubMed ID: 18084763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
    Atzpodien J; Terfloth K; Fluck M; Reitz M
    Am J Clin Oncol; 2011 Feb; 34(1):2-5. PubMed ID: 20042970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 593.